NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Market Closed 02-14 16:00:00 EST

2.85

-0.09

-3.06%

盘后3.01

+0.16+5.61%

19:55 EST

High3.07	Low2.82	Vol281.62K
Open2.93	D1 Closing2.94	Amplitude8.50%
Mkt Cap34.47M	Tradable Cap28.43M	Total Shares12.09M
T/O818.74K	T/O Rate2.82%	Tradable Shares9.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":2.85,"timestamp":1739566800000,"preClose":2.94,"halted":0,"volume":281616,"hourTrading":{"tag":"盘后","latestPrice":3.01,"preClose":2.85,"latestTime":"19:55 EST","volume":17065,"amount":48541.3379,"timestamp":1739580929845},"delay":0,"floatShares":9974754,"shares":12094100,"eps":-2.124018,"marketStatus":"Market Closed","change":-0.09,"latestTime":"02-14 16:00:00 EST","open":2.93,"high":3.07,"low":2.82,"amount":818743.2669408,"amplitude":0.085034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.124018,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.94,"preHourTrading":{"tag":"盘前","latestPrice":2.89,"preClose":2.94,"latestTime":"09:29 EST","volume":1584,"amount":4601.619792,"timestamp":1739543370105},"postHourTrading":{"tag":"盘后","latestPrice":3.01,"preClose":2.85,"latestTime":"19:55 EST","volume":17065,"amount":48541.3379,"timestamp":1739580929845},"volumeRatio":1.142484373009182,"impliedVol":1.8248,"impliedVolPercentile":0.5697},"requestUrl":"/m/hq/s/NRXP/tweets","defaultTab":"tweets","newsList":[{"id":"2509275937","title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509275937","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509275937?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:03","pubTimestamp":1738846980,"startTime":"0","endTime":"0","summary":"Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New York February 10th-12th. The presentation is scheduled for Wednesday, February 12th, from 9:20 – 9:50 AM EST. A live webcast will be accessible on NRX Events, within the Investor Relations section of the Company's website. A replay of the webcast will also be available for 30 days following the event.Management will also be available for one-on-one meetings in New York from February 10th-12th. To schedule meetings in New York or at the BIO CEO & Investor Conference, please contact sebastian.gomez@astrpartners.com.NRx has recently initiated a New Drug Application filing for NRX-100  for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130300394.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130300394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HOPE","USJW.SI","NRXP","BK4588","LU2095319765.USD","IE00BKPKM429.USD","BK4007","LU2210149790.SGD","TQQQ","BK4139","BK4127","QID","BK4211","TSYW.SI","USAW.SI","NVIW.SI","SQQQ","LU2210150020.SGD","IE00BGHQF748.EUR","NDAQ","QLD","NQmain","LENZ","BK4137","BK4112","MNQmain","IE00B64PRP62.GBP","PSQ","BK4585","NRXPW","IE00B3QW5Z07.USD","HCSG","OPY",".IXIC"],"gpt_icon":1},{"id":"2508414590","title":"NRx Pharmaceuticals, Hope Therapeutics engage BTIG as financial advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2508414590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508414590?lang=en_us&edition=fundamental","pubTime":"2025-02-03 22:07","pubTimestamp":1738591635,"startTime":"0","endTime":"0","summary":"Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services firm ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-hope-therapeutics-engage-btig-as-financial-advisor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-hope-therapeutics-engage-btig-as-financial-advisor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","LENZ","NRXP","HOPE","BK4007","BK4139"],"gpt_icon":0},{"id":"2508145982","title":"HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2508145982","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508145982?lang=en_us&edition=fundamental","pubTime":"2025-02-03 21:59","pubTimestamp":1738591140,"startTime":"0","endTime":"0","summary":"HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial magnetic stimulation, and digital therapeutics to treat severe depression and PTSD. BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and related brokerage services. The information in this press release is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hope-therapeutics-inc-nrx-pharmaceuticals-135900037.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hope-therapeutics-inc-nrx-pharmaceuticals-135900037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210149790.SGD","IE00BKPKM429.USD","BK4211","LENZ","LU2210150020.SGD","NRXPW","BK4585","QLD","NQmain",".IXIC","NRXP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","USAW.SI","NVIW.SI","BK4007","BK4588","TQQQ","USJW.SI","TSYW.SI","NDAQ","HOPE","BK4139","LU2095319765.USD","SQQQ","BK4112","MNQmain","IE00B64PRP62.GBP","PSQ","QID"],"gpt_icon":1},{"id":"2507540297","title":"NRX Pharmaceuticals Unit Secures $27 Million Funding; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2507540297","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507540297?lang=en_us&edition=fundamental","pubTime":"2025-01-29 03:49","pubTimestamp":1738093775,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals'  Hope Therapeutics unit said Tuesday it has entered into a stock purchase agreement with Smith & Sauer for a $27 million financing round to fund the planned purchase of Hope clinics.The agreement includes an immediate $2 million investment in NRx common stock and Smith & Sauer committing to buy Hope's Series A preferred shares worth $25 million. An initial sum of $6.75 million of the $25 million is due Feb. 7, while the remaining amount is due April 1, the company's unit said.The funds will be used to expand Interventional Psychiatry Clinics for the treatment of severe depression and other psychological disorders, it added.The company expects to generate revenues of $100 million by the end of 2025 through the clinic roll-up, Hope said.NRx is also working with an investment bank to secure $400 million to further expand its national and international footprint, according to the company's chairman, Jonathan Javitt.Shares of NRx jumped 28% in recent trading.Price: 3.65","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2506513273","title":"NRx Pharmaceuticals invests $27M in subsidiary Hope for clinic acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2506513273","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506513273?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:15","pubTimestamp":1738070148,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals (NRXP)’ wholly-owned subsidiary Hope Therapeutics signed a Stock Purchase Agreement with Smith & Sauer as the first step in a $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-invests-27m-in-subsidiary-hope-for-clinic-acquisitions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-invests-27m-in-subsidiary-hope-for-clinic-acquisitions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXP","BK4007","HOPE","BK4211"],"gpt_icon":0},{"id":"2506513342","title":"Hope Therapeutics™, Inc. and NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Execute Agreement for $27 Million Funding Transaction for Hope Clinic Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2506513342","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506513342?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:05","pubTimestamp":1738069503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nTUA4WHJZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2506674513","title":"Press Release: HOPE Therapeutics(TM), Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2506674513","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506674513?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:05","pubTimestamp":1738069500,"startTime":"0","endTime":"0","summary":"HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc.  Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition. -- $25 million investment in HOPE to consist of Series A (non-dilutive to. NRx shareholders) convertible into 1/3 of fully diluted HOPE equity, with. -- Initial funding of $2.0 million for purchase of NRx common stock. anticipated to close on or before January 29, with the first tranche of. Therapeutics, Inc. on or before February 7, 2025, and the balance of. initiate nationwide rollup strategy of interventional psychiatry clinics,The Company anticipates leveraging the Smith and Sauer investment with bank debt and similar instruments to fund an initial rollup of Interventional Psychiatry Clinics with anticipated revenues of approximately $100 million on a pro-forma basis by the end of 2025. Unlike \"ketamine clinics\" that are frequently operated by non-mental health professionals, HOPE anticipates building a best-in-class nationwide chain of facilitie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","TQQQ","BK4555","LU2210149790.SGD","LU2095319765.USD","TSYW.SI","BK4139","BK4007","SQQQ","MNQmain","LENZ","QID",".IXIC","TM","BK4112","BK4588","NDAQ","USJW.SI","LU2210150020.SGD","NVIW.SI","USAW.SI","HOPE","IE00B3QW5Z07.USD","PSQ","BK4211","03160","IE00B64PRP62.GBP","BK4099","NRXP","BK4585","NQmain","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2506850513","title":"NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Advances Relationship With Anson Funds With $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2506850513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506850513?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:03","pubTimestamp":1738069394,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO1FI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2506515385","title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2506515385","media":"PR Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506515385?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:03","pubTimestamp":1738069380,"startTime":"0","endTime":"0","summary":"This financing is expected to support filing of New Drug Applications forNRX-100  and NRX-101, and to support launch of HOPE Therapeutics. Investment consists of $3.5 million in above the market equity and $5.4 million in Senior Secured Notes; expected to fund current operations into 2026. \"We are delighted to continue working with NRx Pharmaceuticals in their development of a very promising pipeline, with two medicines with potential to transform the lives of patients with suicidal depression and their loved ones. We look forward to potential registrations and approvals of these products,\" said Amin Nathoo, Principal, Anson Funds.In connection with the Financing, the Company will issue to the investors approximately 1.2 million shares of common stock  at $2.88 per share and an equal number of common stock purchase warrants with an exercise of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130300548.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130300548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","NDAQ","TSYW.SI","BK4215","BK4585","LU2210149790.SGD","BK4112",".IXIC","NVIW.SI","IE00B64PRP62.GBP","NQmain","EQR","USJW.SI","QLD","USAW.SI","TQQQ","IE00BKPKM429.USD","SQQQ","NRXPW","MNQmain","BK4007","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","PSQ","NRXP","BK4588","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2505227985","title":"NRX Pharmaceuticals, Inc. (Nasdaq: Nrxp) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2505227985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505227985?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:02","pubTimestamp":1737464529,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH0OC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2505227134","title":"NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2505227134","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505227134?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:02","pubTimestamp":1737464520,"startTime":"0","endTime":"0","summary":"Company received written notice from the Nasdaq Listing Qualifications Staff stating that the Company regained compliance with the applicable Nasdaq minimum market value of listed securities continued listing requirement. WILMINGTON, Del., Jan. 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company, today announced that on January 17, 2025, it received written notice from the Nasdaq Listing Qualifications Staff  stating that the Company regained compliance with the market value of listed Securities  requirement, as set forth in Nasdaq Listing Rule 5550  for continued listing on the Nasdaq Capital Market, and the matter is now closed.The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding closing the acquisition of Kadima and obta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130200042.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130200042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","NRXPW","TSYW.SI","USAW.SI","BK4585","IE00BKPKM429.USD",".IXIC","NVIW.SI","BK4007","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR","NQmain","QID","QLD","NRXP","PSQ","IE00B3QW5Z07.USD","MNQmain","BK4588","BK4112","SQQQ","TQQQ","NDAQ","USJW.SI","LU2210150020.SGD"],"gpt_icon":1},{"id":"2503364353","title":"NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces the Appointment of Michael Taylor to Its Board of Directors and Appointment of Anita Nunes as Board Observer; MS. Nunes to Be Appointed Director of Hope Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2503364353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503364353?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:02","pubTimestamp":1736946124,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUABVLDR8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2503643196","title":"Press Release: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2503643196","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503643196?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:02","pubTimestamp":1736946120,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals, Inc.  Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.A graduate of the London School of Economics with a Bachelor of Science in Economics and International Relations, Michael has built a reputation for navigating complex financial environments and delivering innovative solutions. These skills will be integral to the growth of the HOPE clinic network.  He joins NRx Pharmaceuticals as the Board Designee of Smith & Sauer, LLC, following the recently announced financing.In addition to her work at Smith & Sauer, Anita is the Founder of Mocktail Nation, a health-conscious beverage brand, and Pluzze Consulting, where she has provided strategic guidance to empower entrepreneurs and investors. Her ability to align financial strategies with impactful outcomes has positioned her as a leader in purpose-driven investments, del","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875086.SGD","LU2271345857.HKD","LU1989772923.USD","QID","TSYW.SI","NQmain","LU0267386448.USD","BK4534","HOPE","LU2028103732.USD","BK4139","LU0106831901.USD","LU2347655156.SGD","NDAQ","BK4211","SQQQ","LU0158827948.USD",".IXIC","LU0971096721.USD","LU0106261372.USD","IE00BZ1G4Q59.USD","BK4581","LU0225283273.USD","LU1732800096.USD","LU0320765646.SGD","PSQ","LU2023251221.USD","LU2357305700.SGD","LU2089283258.USD","LU2210150020.SGD","TQQQ","NRXP","LU1720051017.SGD","LU0158827781.USD","LU0912757837.SGD","NVIW.SI","BK4516","LU2089284900.SGD","USJW.SI","LU0098860793.USD","MNQmain","QLD","LU0314104364.USD","LENZ","LU1989772840.SGD","USAW.SI","LU1732799900.SGD","BK4007","LU1074936037.SGD"],"gpt_icon":1},{"id":"2503052700","title":"Press Release: HOPE Therapeutics(TM), Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2503052700","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503052700?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:03","pubTimestamp":1736859780,"startTime":"0","endTime":"0","summary":"-- \"'Special K': The Science & Stigma of Ketamine\" on CNN, hosted by Dr.-- David Feifel MD PHD, Founder of Kadima, is a global thought leader in the. -- Kadima Neuropsychiatry Institute identified as planned HOPE Flagship. MIAMI, Jan. 14, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., , a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc.  , today alerted investors that Kadima Neuropsychiatry Institute's Founder David Feifel, MD PHD was featured as an expert in a program on ketamine entitled \"'Special K': The Science & Stigma of Ketamine\" on CNN, hosted by Dr. Sanjay Gupta. HOPE previously announced that Kadima is identified as the Company's planned flagship clinic acquisition, upon closing of the transaction.\"The recent, tragic death of Mathew Perry underscores the need for people with depression to have access to psychiatric centers of excellence where they can receive ketamine and other advanced treatments at the highest standard of medi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LENZ","TSYW.SI","USAW.SI","BK4585","IE00BKPKM429.USD",".IXIC","NVIW.SI","BK4007","LU2095319765.USD","BK4555","03160","BK4139","IE00BGHQF748.EUR","LU2210149790.SGD","NQmain","QID","BK4099","TM","QLD","ISBC","BK4211","NRXP","PSQ","IE00B3QW5Z07.USD","HOPE","MNQmain","BK4588","BK4112","SQQQ","TQQQ","NDAQ","USJW.SI","LU2210150020.SGD"],"gpt_icon":1},{"id":"2503301514","title":"NRx Pharmaceuticals files to uplist securities to Nasdaq Global Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2503301514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503301514?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:16","pubTimestamp":1736774186,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals (NRXP) announced it has applied to Nasdaq to uplist the company’s securities to the Nasdaq Global Market. The company has advis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-files-to-uplist-securities-to-nasdaq-global-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-files-to-uplist-securities-to-nasdaq-global-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","QLD","SQQQ","PSQ","LU2095319765.USD","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ","NQmain","USJW.SI","QID","NRXP","IE00BKPKM429.USD","TSYW.SI","BK4007","BK4585","BK4588","LU2210149790.SGD",".IXIC","TQQQ","MNQmain","NVIW.SI","USAW.SI","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2503096003","title":"NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces It Has Filed an Application With Nasdaq to Uplist to the Nasdaq Global Market From the Nasdaq Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2503096003","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503096003?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:04","pubTimestamp":1736773448,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O90QB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2503304822","title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2503304822","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503304822?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:04","pubTimestamp":1736773440,"startTime":"0","endTime":"0","summary":"Management believes uplisting has the potential to provide shareholders with improved liquidity. Requires NRx Pharmaceuticals to meet certain listing requirements. Company has advised NASDAQ that current shares outstanding is 15.7 million. WILMINGTON, Del., Jan. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company, today announced it has applied to NASDAQ to uplist the Company's securities to the NASDAQ Global Market .Listing on the NASDAQ Global Market requires the Company to meet published requirements to successfully list on the NASDAQ Global Market, including maintaining a market value of listed securities  above $75 million and a minimum bid price of at least $4.00 for 90 consecutive trading days. The Company has advised NASDAQ that it currently has 15.7 million outstanding shares of common stock, which will inform the calculation of the Company's market capitalization.The information contained herein includes forward-looking statements ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130400170.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130400170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","NVIW.SI","BK4585","IE00B64PRP62.GBP","USJW.SI",".IXIC","USAW.SI","QID","NRXPW","BK4007","NRXP","BK4112","PSQ","LU2210149790.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","NQmain","BK4588","QLD","TSYW.SI","SQQQ","TQQQ","IE00B3QW5Z07.USD","MNQmain"],"gpt_icon":1},{"id":"2502863320","title":"HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club","url":"https://stock-news.laohu8.com/highlight/detail?id=2502863320","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502863320?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:04","pubTimestamp":1736514240,"startTime":"0","endTime":"0","summary":"MIAMI, Jan. 10, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., , a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc.  , today announced it conducted an investor workshop to support planned expansion of HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL.The event was attended by Qualified Institutional Buyers as defined by the Securities and Exchange Commission and included Jonathan Javitt, MD, MPH, Chairman and CEO of NRx together with Dallas Sauer, Founder of Smith and Sauer, the private investment firm that recently committed to invest in both NRx and HOPE. No formal meetings were conducted with members of the incoming administration.HOPE's mission to build an international network of best-in class, EBITDA positive, interventional psychiatry clinics. $25 million financing committed by Smith and Sauer  to leverage anticipated bank financi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hope-therapeutics-inc-nrx-pharmaceuticals-130400648.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hope-therapeutics-inc-nrx-pharmaceuticals-130400648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","USJW.SI","IE00B64PRP62.GBP","LU2210149790.SGD","QID","IE00B3QW5Z07.USD","SQQQ","BK4139","BK4211","BK4588","TQQQ","NQmain","LU2210150020.SGD","NDAQ",".IXIC","LENZ","NRXPW","BK4007","NVIW.SI","QLD","TSYW.SI","BK4585","PSQ","HOPE","MNQmain","USAW.SI","BK4112","LU2095319765.USD","NRXP"],"gpt_icon":1},{"id":"2501646206","title":"HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco","url":"https://stock-news.laohu8.com/highlight/detail?id=2501646206","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501646206?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:07","pubTimestamp":1736255220,"startTime":"0","endTime":"0","summary":"The Keynote Address, entitled \"Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD,\" will be presented at 10:30AM PT on Sunday January 12th, 2025. Prof. DavidFeifel MD PHD, designated Chief Medical Innovation Officer of HOPE and Founder of the Kadima Neuropsychiatry Institute, is an international thought leader in the interventional psychiatry space. NRx Pharmaceuticals recently initiated filing of its NDA for NRX-100  for the treatment of suicidal depression. The Sachs Forum, held annually during the JP Morgan Healthcare Conference week, brings together leaders and innovators in neuroscience to explore cutting-edge advancements in therapeutics, neurotechnology, and diagnostics. Lifesaving therapies for CNS diseases that are widely deployed today were first presen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hope-therapeutics-inc-nrx-pharmaceuticals-130700035.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hope-therapeutics-inc-nrx-pharmaceuticals-130700035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRXPW","LU2210150020.SGD","IE00B3QW5Z07.USD","NQmain","NVIW.SI","IE00BKPKM429.USD","TQQQ","QID",".IXIC","NDAQ","BK4007","IE00B64PRP62.GBP","TSYW.SI","IE00BGHQF748.EUR","USAW.SI","BK4585","BK4178","PSQ","BK4211","LU2210149790.SGD","FET","HOPE","BK4112","NRXP","SQQQ","BK4179","BK4139","USJW.SI","MNQmain","QLD","BK4588","LU2095319765.USD","LENZ"],"gpt_icon":1},{"id":"2501292804","title":"NRx Pharmaceuticals' Acquisition Likely to Result in Multiple Avenues of Growth -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2501292804","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501292804?lang=en_us&edition=fundamental","pubTime":"2025-01-07 08:00","pubTimestamp":1736208000,"startTime":"0","endTime":"0","summary":"1857 ET [Dow Jones]--NRx Pharmaceuticals plans to acquire Dura Medical and invest $27 million to establish a network of interventional psychiatry clinics, offering services such as ketamine-infusion treatments. This plan positions NRx for growth through expanded services for civilian and veteran communities, D. Boral Capital analysts say in a research note. They add that the plan is also expected to deliver immediate financial benefits, with the acquisition anticipated to be accretive to revenue and earnings before interest, taxes, depreciation and amortization. \"The integration of Dura into the HOPE network underscores NRx's commitment to addressing critical mental health needs, particularly among veterans and underserved populations,\" analysts write. Shares edge higher in postmarket trading after ending the regular session up 30%, to $3.51. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":-0.0306},{"period":"1month","weight":-0.3653},{"period":"3month","weight":1.395},{"period":"6month","weight":0.6474},{"period":"1year","weight":-0.4112},{"period":"ytd","weight":0.2955}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.036883},{"month":2,"riseRate":0.25,"avgChangeRate":-0.051873},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.073314},{"month":4,"riseRate":0,"avgChangeRate":-0.311577},{"month":5,"riseRate":0.666667,"avgChangeRate":0.013246},{"month":6,"riseRate":0.25,"avgChangeRate":-0.267026},{"month":7,"riseRate":0.5,"avgChangeRate":0.093346},{"month":8,"riseRate":0.25,"avgChangeRate":-0.143251},{"month":9,"riseRate":0.25,"avgChangeRate":-0.121573},{"month":10,"riseRate":0.75,"avgChangeRate":0.062005},{"month":11,"riseRate":0.5,"avgChangeRate":0.112968},{"month":12,"riseRate":0.5,"avgChangeRate":0.12575}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction